NEUP Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. (NEUP) is expected to report earnings on August 28, 2026, before the market open. The consensus earnings estimate is a loss of $0.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -24.1% since its last earnings release on May 15, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Neuphoria Therapeutics Inc.
Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.
Sector
Healthcare
Industry
Biotechnology